Esbjerg Hospital - University Hospital of Southern Denmark — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Esbjerg Hospital - University Hospital of Southern Denmark appears in 34 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials34

Recruiting shown8

Roles2

SourceClinicalTrials.gov

Clinical trials

34 shown

Cortisol and Obesity - A Vicious Cycle? Hypoglycemia After Bariatric Surgery - Association With Cortisol Metabolism?NCT06896682 · lead sponsor · 2025-07-08

Mediterranean Diet and Inequality in Early Breast CancerNCT07007169 · lead sponsor · 2025-03-27

Predictive Utility of a Short-term Improvement in Objectively Measured Physical Activity in Rheumatoid Arthritis (PUSIPA)NCT06289114 · lead sponsor · 2023-09-01

Prognostic Significance of Fatty Liver Disease in Bariatric PatientsNCT03535142 · lead sponsor · 2018-08-15

Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)NCT06790225 · lead sponsor · 2025-11-10

Tailoring Obesity Treatment TrialNCT06619015 · lead sponsor · 2025-04-01

Protocol for a Diagnostic Test Accuracy of Histological Muscle and Skin Biopsies of Rheumatoid Arthritis Patients Revealing Objective Chronic Widespread Pain Phenomena Related to FibromyalgiaNCT06305026 · lead sponsor · 2024-02-07

A Weight-Neutral Approach for a Healthier Lifestyle Among Obesity - A Lifestyle Intervention Anchored in SDOINCT05708417 · lead sponsor · 2023-02-01

Sleep, Obesity and Mental Disease - Biological Markers for the Evaluation of Circadian RhythmicityNCT05413486 · lead sponsor · 2022-04-04

Covid-19 Infection and New Onset Type 1 DiabetesNCT04623697 · lead sponsor · 2020-11-01

Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute ExacerbationNCT04223050 · lead sponsor · 2020-02-03

Meal-induced Thrombin Generation Before and After Gastric BypassNCT03176615 · lead sponsor · 2017-09-01

The Diabetes Patient Takes ResponsibilityNCT03083899 · lead sponsor · 2017-03-01

DD2-Coronary Plaque Morphology and Plaque ProgressionNCT03022344 · lead sponsor · 2014-11-01

Effect of Physical Therapy on Breast Cancer Related LymphedemaNCT02015897 · lead sponsor · 2014-01-01

Effect of Physical Activity on Weight Loss and Cardiovascular Risk Factors After Gastric BypassNCT01690728 · lead sponsor · 2012-10-01

Different Insulin Regimens and Postprandial Coagulation ActivationNCT01053234 · lead sponsor · 2007-02-01

Effects of Nordic Walking and Exercise on Glucose Metabolism in Type 2 Diabetes Mellitus: A Randomized Controlled TrialNCT01085773 · lead sponsor · 2005-02-01

Prevention of Preeclampsia in Denmark: A National Implementation StudyNCT07485140 · collaborator · 2025-09-15

Prehabilitation to Patients With Prostate CancerNCT07162987 · collaborator · 2025-08-04

Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to InclusionNCT06949319 · collaborator · 2024-08-16

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesNCT06082063 · collaborator · 2024-07-01

Antenatal Breastmilk Expression in Pregnant Women at High Risk of Preterm BirthNCT07191366 · collaborator · 2026-09-01

NOT_YET_RECRUITING

A Precision Medicine Approach to the Prevention of Depression in Patients With Atrial FibrillationNCT07178691 · collaborator · 2024-04-19

Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF PatientsNCT04885634 · collaborator · 2022-10-01

the Type ONe dIabetic Bone Collaboration StudyNCT05673837 · collaborator · 2021-12-10

PRISMA-PET - Primary Staging of Prostate Cancer With PSMANCT05123300 · collaborator · 2021-10-04

Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid ArthritisNCT04842981 · collaborator · 2021-05-25

Chronic Inflammatory Disease, Lifestyle and Treatment ResponseNCT03173144 · collaborator · 2017-09-21

Insulin Degludec and Symptomatic Nocturnal HypoglycaemiaNCT02192450 · collaborator · 2015-01-01

Long-Term Integrated Telerehabilitation of COPD Patients. A Multi-Center TrialNCT02258646 · collaborator · 2014-10-01

Liraglutide in Newly Onset Type 1 Diabetes.NCT01879917 · collaborator · 2014-02-01

Individually Tailored Treatment of Type 2 DiabetesNCT02015130 · collaborator · 2013-10-01

Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic DisordersNCT01571609 · collaborator · 2012-08-01

Drugs studied in this sponsor's trials

10 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Esbjerg Hospital - University Hospital of Southern Denmark as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

placebo2

25 ML sodium chloride 9 MG/ML Injection1

finerenone1

liraglutide1

pramlintide acetate 1 MG/ML1

sarilumab1

semaglutide1

semaglutide Pen Injector1

placebo RxCUI 8375 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials 25 ML sodium chloride 9 MG/ML Injection RxCUI 1807630 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial finerenone RxCUI 2562811 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial liraglutide RxCUI 475968 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial pramlintide acetate 1 MG/ML RxCUI 861034 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial sarilumab RxCUI 1923319 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial semaglutide RxCUI 1991302 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial semaglutide Pen Injector RxCUI 1991305 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial sotagliflozin RxCUI 2638675 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial tocilizumab RxCUI 612865 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor18

collaborator16

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.